Landmark Achievement in Pharmaceutical Chemistry
Merck scientists have achieved a remarkable 14-fold increase in the production yield of enlicitide decanoate, an investigational oral PCSK9 inhibitor, by merging traditional chemistry with engineered enzymes. The breakthrough, published in the journal Science, demonstrates how directed evolution can transform pharmaceutical manufacturing.
Enlicitide is one of the most promising drugs in Merck's pipeline, currently in late-stage clinical trials for both cholesterol reduction and weight management. The drug has been shown to reduce LDL or bad cholesterol by up to 60 percent in phase 3 trials, matching the efficacy of injectable PCSK9 inhibitors while being available as a simple oral pill.
How the Yield Breakthrough Was Achieved
Merck's team split the enlicitide molecule into three segments called Northern, Eastern, and Western. The Eastern and Western parts were synthesised using conventional chemistry, but the Northern segment, containing unnatural amino acids, required a different approach.
The researchers used directed evolution to engineer seven custom enzymes. These seven enzymes, combined with three natural enzymes, were able to assemble the fragments and close the final ring structure. The process achieved a yield of 70 grams per litre at over 99 percent purity, representing a 14-fold improvement.
What This Means for Enlicitide's Development
The improved manufacturing process could significantly reduce the cost of producing enlicitide, potentially making the drug more affordable and accessible. High manufacturing costs have been a major barrier for biologic drugs, and this breakthrough could serve as a template for producing other complex pharmaceutical molecules.
Enlicitide is being studied for multiple indications including cholesterol management and weight loss. Its oral formulation is a key differentiator, as injectable PCSK9 inhibitors have seen limited adoption despite their efficacy.
Directed Evolution: The Technology Behind the Breakthrough
Directed evolution, pioneered by Nobel laureate Frances Arnold, involves creating libraries of enzyme variants through random mutation and selecting those with desired properties. Merck's application represents one of the most ambitious industrial uses of this technique to date.
The final enzyme cocktail represents one of the most complex multi-enzyme cascades ever deployed in commercial pharmaceutical manufacturing.
Broader Implications for Drug Manufacturing in India and Globally
This breakthrough has significant implications for India's pharmaceutical industry, the world's largest producer of generic drugs. Indian pharmaceutical companies could benefit from similar directed evolution approaches to improve yields of complex molecules. For Indian patients, improved manufacturing efficiency could mean faster access to advanced therapies at lower costs.
Sources
Sources: Science Journal (DOI: 10.1126/science.aed8713), UT Southwestern Medical Center, Drugs.com, PharmaVoice, Works in Progress Newsletter
